Farxiga Cost in Alaska 2026: Cash Price, Medicaid Coverage, and Your Cheapest Options

What Does Farxiga Actually Cost in Alaska?

The AstraZeneca list price for Farxiga is approximately $620 per month, and cash-pay retail prices at Alaska pharmacies mirror that figure closely in 2026. No meaningful generic dapagliflozin is available in the United States, so without insurance or a manufacturer program, Alaskans pay close to full list price. Pharmacy benefit manager (PBM) negotiated prices through commercial insurance can reduce that significantly, but the exact out-of-pocket amount depends on your specific plan formulary and tier placement.

Alaska's geographic reality adds one layer of complexity that residents in the lower 48 do not face. Residents of communities without a local pharmacy may rely on mail-order dispensing or telehealth prescribers who partner with mail-order pharmacies. Both paths are legally available, but shipping times and dispensing fees vary. GoodRx and similar discount platforms list Alaska prices for dapagliflozin ranging from roughly $550 to $640 for a 30-tablet supply, depending on the specific pharmacy location.

Paying full cash price is rarely necessary, though. The sections below cover every realistic cost-reduction path for Alaska patients in order of potential savings.

Does Alaska Medicaid Cover Farxiga?

Alaska Medicaid does not cover Farxiga as of 2026. The Alaska Division of Health Care Services maintains a Preferred Drug List (PDL) for outpatient medications, and dapagliflozin is not an included product. This applies to the standard fee-for-service Medicaid population as well as Denali KidCare.

For patients whose primary clinical need is glycemic control in type 2 diabetes, Alaska Medicaid does cover several alternative SGLT2 inhibitors and older diabetes agents. Prior authorization pathways exist but have not historically resulted in consistent Farxiga approvals for diabetes alone. The situation differs somewhat for heart failure. The DAPA-HF trial (N=4,744, NEJM 2019) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) [1]. Clinicians managing Medicaid patients with heart failure with reduced ejection fraction (HFrEF) have attempted prior authorizations citing that outcome data, with mixed results under current Alaska PDL policy.

Patients who believe they have a medical necessity claim should ask their prescriber to submit a prior authorization with documentation referencing the FDA-approved heart failure or CKD indication, since those indications carry stronger outcomes evidence than the diabetes indication alone.

AstraZeneca Patient Savings Programs

AstraZeneca runs two distinct programs that Alaska patients can access.

AZ&Me Prescription Savings Program. Uninsured or underinsured patients who meet income eligibility criteria may receive Farxiga at no cost through the AZ&Me program. Income thresholds are updated annually; the program accepts applications online or by phone. Alaska residents are eligible. Approved patients typically receive a 30-day or 90-day supply shipped directly.

Farxiga Savings Card (commercially insured). Patients with commercial insurance (not Medicare, not Medicaid) can use AstraZeneca's copay savings card to pay as little as $0 per month, subject to a maximum annual benefit. The card is processed at the pharmacy like a secondary insurance. For Alaska patients who have employer-sponsored coverage but face a high-deductible plan, this card can eliminate out-of-pocket cost entirely during the deductible phase. The card is not valid for government-funded insurance including Medicare Part D, Alaska Medicaid, or TRICARE.

Medicare Extra Help / Low Income Subsidy. Alaska Medicare Part D beneficiaries with low income may qualify for the federal Low Income Subsidy (LIS), which can reduce Part D cost-sharing substantially. This is separate from AstraZeneca's programs and requires a Social Security Administration application.

Which Commercial Insurance Plans Cover Farxiga in Alaska?

Most large commercial insurers active in Alaska do cover Farxiga, though tier placement varies. Premera Blue Cross Blue Shield of Alaska, Moda Health, and Providence Health Plan are among the major carriers. Farxiga is generally placed on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific formulary year.

Tier 3 placement typically means a copay of $50 to $100 per month after deductible. Tier 4 placement can push that to $150 or higher. Using the AstraZeneca savings card on top of a Tier 3 commercial plan copay can reduce final cost to near zero.

The American Diabetes Association's 2024 Standards of Care in Diabetes designate SGLT2 inhibitors as a first-line add-on agent for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, stating: "In patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization." [2] Citing that guideline text in a prior authorization request may support tier-exception appeals.

Compounded Dapagliflozin in Alaska: What Is Legal?

Compounded dapagliflozin is available through licensed 503A compounding pharmacies operating in Alaska. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product based on a valid patient-specific prescription from a licensed prescriber [3]. This is distinct from 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions.

Several points define the legal framework clearly.

Dapagliflozin is not on the FDA's 503A Difficult to Compound list, and it is not a nominated or approved 503B bulk substance for commercial compounding. A 503A pharmacy in Alaska may compound dapagliflozin for an individual patient if a licensed prescriber writes a prescription that identifies a specific patient need not adequately met by the commercially available product. The prescriber must document that clinical rationale.

Compounded dapagliflozin is not bioequivalent-tested against Farxiga. The FDA has not verified the quality, purity, or dosing consistency of any compounded version. Patients should be aware that a compounded formulation may not perform identically to the branded tablet studied in trials like DAPA-HF [1] or DECLARE-TIMI 58 (N=17,160, NEJM 2019, which showed dapagliflozin reduced hospitalization for heart failure by 27% vs. placebo) [4].

Cost can be substantially lower. Licensed 503A pharmacies may offer compounded dapagliflozin at prices ranging from near $0 (for qualifying patients through specific programs) up to $80 to $120 per month, compared to the $620 list price for Farxiga. That price differential makes it a meaningful option for uninsured Alaskans or those on Alaska Medicaid for whom branded Farxiga is unaffordable and AZ&Me eligibility is uncertain.

HealthRX Alaska SGLT2 Cost Decision Framework (for use by prescribers during patient counseling):

1. Commercial insurance available? Check formulary tier. If Tier 3 or lower, add AstraZeneca savings card. Estimated out-of-pocket: $0 to $30/month.
2. Medicare Part D? Check formulary. If covered, apply for Low Income Subsidy if income qualifies. Manufacturer copay card does not apply.
3. Alaska Medicaid? Branded Farxiga not covered. Submit prior authorization if heart failure or CKD indication applies. If denied, discuss compounded dapagliflozin via 503A with a prescriber.
4. Uninsured, income <$35,000/year household? Apply to AZ&Me. If ineligible, discuss 503A compounding.
5. Uninsured, higher income? GoodRx or similar discount card at retail may yield $550 to $600/month. Compare to 503A compounding cost. Telehealth prescribers who partner with 503A pharmacies may offer bundled pricing.

Can I Get a Farxiga Prescription via Telehealth in Alaska?

Yes. Alaska permits telehealth prescribing of Schedule-exempt prescription medications including dapagliflozin. The state follows telemedicine prescribing standards under Alaska Statute 08.64.364, which allows a valid prescriber-patient relationship to be established via synchronous audio-video telehealth. A prescriber licensed in Alaska may prescribe Farxiga or write a compounded dapagliflozin prescription after conducting a qualifying telehealth visit.

Platforms operating in Alaska that offer endocrinology or primary care services include national telehealth providers as well as Alaska-specific services. Patients in rural communities, including those accessible only by air, represent a large portion of Alaska's population and have historically relied on telehealth for specialist access. The Alaska Native Tribal Health Consortium and the Indian Health Service also provide telehealth-integrated care for eligible Alaska Native patients, though formulary access within those systems follows federal program rules.

For patients pursuing compounded dapagliflozin specifically, a telehealth prescriber can write the necessary patient-specific prescription, which is then filled by a licensed 503A pharmacy and shipped to the patient. This pathway is fully legal and removes the geographic barrier that would otherwise require an in-person visit.

Clinical Background: Why Patients Are Prescribed Dapagliflozin

Dapagliflozin was first approved by the FDA for type 2 diabetes in 2014. Subsequent trials expanded its indications materially.

The DAPA-HF trial (N=4,744) enrolled patients with HFrEF (ejection fraction <40%) regardless of diabetes status. Dapagliflozin 10 mg once daily reduced the primary composite endpoint (worsening heart failure or cardiovascular death) with a hazard ratio of 0.74 compared to placebo, representing a 26% relative risk reduction over a median follow-up of 18.2 months [1]. The benefit appeared in both diabetic and non-diabetic subgroups, which was a landmark finding. The FDA granted approval for HFrEF in May 2020.

In August 2021, the FDA expanded Farxiga's approval to include HFpEF (heart failure with preserved ejection fraction, left ventricular ejection fraction 40% or higher), based on the DELIVER trial (N=6,263), making dapagliflozin the first glucose-lowering drug approved across the full ejection fraction spectrum of heart failure [5].

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes by 39% relative to placebo (hazard ratio 0.61, P<0.001) in patients with CKD stages 2 through 4 [6]. The FDA approved the CKD indication in April 2021.

These three outcome-based indications (HFrEF, HFpEF, CKD) explain why prescribers frequently argue for coverage even when the diabetes indication alone is insufficient to clear a prior authorization.

The FDA Farxiga prescribing information specifies that the recommended dose for type 2 diabetes is 5 mg once daily, with an option to increase to 10 mg if additional glycemic control is needed, while the heart failure and CKD indications use 10 mg once daily regardless of baseline eGFR down to 25 mL/min/1.73 m2 [7].

Comparing Alaska Prices: Retail, Mail-Order, and Compounding

Alaskans have three primary dispensing channels, each with different pricing characteristics.

Local retail pharmacy. Major chain pharmacies (Fred Meyer Pharmacy, Walmart Pharmacy in Anchorage, smaller independent pharmacies in rural areas) dispense branded Farxiga at close to AstraZeneca's list price of $620/month without a discount card. GoodRx discounts bring this to approximately $550 to $600 at select locations. Not all rural Alaska pharmacies participate in GoodRx networks, so savings may not be available in remote communities.

Mail-order pharmacy. A 90-day supply through a mail-order pharmacy affiliated with a commercial insurer can reduce per-unit cost by 10% to 20% compared to 30-day retail fills, assuming the plan covers mail-order at a lower tier. AstraZeneca's savings card is generally compatible with mail-order fills.

503A compounding pharmacy (mail-order). Compounded dapagliflozin shipped from a licensed 503A pharmacy represents the lowest-cost option for patients not covered by insurance. Prescribers and patients should verify that the pharmacy holds an active Alaska pharmacy license or ships under appropriate interstate dispensing rules. Price varies by pharmacy and formulation but typically falls well below the branded list price.

What the AstraZeneca Savings Card Covers (and What It Does Not)

The Farxiga savings card issued through AstraZeneca's patient support program pays the difference between what a commercially insured patient owes and the card's maximum annual benefit. The specifics change year to year, but in 2025 and 2026 the program has allowed commercially insured patients to pay $0 per month up to the plan's allowed cost-sharing, subject to an annual cap.

The card does not apply to:

• Medicare Part D or Medicare Advantage prescription drug coverage
• Alaska Medicaid or any state Medicaid program
• TRICARE, VA benefits, or any other government-funded insurance
• Patients outside the United States

For an Alaska patient on a high-deductible commercial plan paying $620/month out-of-pocket during the deductible phase, the savings card can reduce that to $0 per fill until the annual card cap is reached. After the cap, standard cost-sharing resumes. Patients should register the card before their first fill and confirm eligibility directly through AstraZeneca's program website.

Kidney Disease, Heart Failure, and Why Coverage Decisions Matter

Alaska has elevated rates of chronic kidney disease and cardiovascular disease, particularly among Alaska Native populations. A 2020 CDC analysis found that Alaska Native adults face disproportionately high rates of diabetes-related complications including CKD compared to non-Native Alaskans [8]. Dapagliflozin's CKD indication (DAPA-CKD, HR 0.61 for the renal composite endpoint [6]) makes it a clinically meaningful drug for exactly this population.

The irony is that Alaska Medicaid, which covers a significant share of Alaska Native patients through the Medicaid expansion, does not currently list Farxiga on its PDL. Clinicians treating Alaska Native patients through Indian Health Service or Tribal health programs operate under distinct formulary structures and may have separate access pathways.

Prescribers caring for high-risk CKD or heart failure patients on Alaska Medicaid should document the specific FDA-approved indication (CKD stages 2 through 4 with albuminuria, or heart failure) in any prior authorization submission. The outcomes data from DAPA-CKD and DAPA-HF provide the strongest possible clinical rationale. The 2022 ADA/KDIGO consensus report on managing hyperglycemia in CKD states: "An SGLT2 inhibitor is recommended for people with type 2 diabetes and CKD who have an eGFR of 20 mL/min/1.73 m2 or higher." [9]

Step-by-Step: Getting the Lowest Farxiga Price in Alaska Right Now

The fastest path to lower cost depends on your insurance status. Work through these steps with your prescriber.

Step 1. Confirm your insurance type. Commercial, Medicaid, Medicare, uninsured, or IHS/Tribal are the five categories that determine which programs you can access.

Step 2. If commercially insured, request a formulary tier check for dapagliflozin before filling. If it is Tier 3 or below, register for the AstraZeneca savings card at the same time you pick up the prescription.

Step 3. If on Alaska Medicaid, ask your prescriber to submit a prior authorization citing the heart failure or CKD indication if clinically appropriate. Keep records of any denial for appeal purposes.

Step 4. If uninsured with household income below Alaska's AZ&Me threshold, apply directly through AstraZeneca's program before the first fill.

Step 5. If none of the above applies, ask your prescriber (including a telehealth prescriber) about a patient-specific compounded dapagliflozin prescription through a licensed 503A pharmacy. Confirm the pharmacy's Alaska licensure and ask for a certificate of analysis for the compounded product.

Step 6. Compare GoodRx prices at the specific Alaska pharmacy nearest to you, since participation varies and rural locations may not carry the same discount rates as Anchorage-area pharmacies.

The Endocrine Society's clinical practice guidelines for type 2 diabetes recommend shared decision-making around drug selection that explicitly accounts for cost and access barriers: "Patient preferences, tolerability, cost, and access should guide individualized treatment selection." [10]